medigraphic.com
Instituto Nacional de Salud Pública

2018, Number 1

<< Back Next >>

salud publica mex 2018; 60 (1)

Antibody prevalence to mumps in children and adolescents at two years of the introduction of the MMR vaccine

Méndez-Herrera A, Arias-Toledo E, Sánchez-Alemán M, Olamendi-Portugal ML, Ruiz-Gómez J, Díaz-Ortega JL

Language: Spanish
References: 34
Page: 71-76
PDF size: 219.42 Kb.


ABSTRACT

Objective. To assess the prevalence of mumps antibodies in children and adolescents of Mexico, two years after the introduction of the mumps-containing vaccine MMR. Materials and methods. Evaluation of IgG antibodies with a commercial kit of indirect ELISA. Results. 2 111 children (1-9 years) and 2 484 adolescents (10-19 years) were studied. The overall antibody seroprevalence was 70.6% (95% CI 69.3- 71.9), being higher in adolescents (83.0%, 95%CI 81.5-84.5) than in children (56.0%, 95%CI: 53.9-58.11) (OR 3.83, 95%CI 3.34-4.39, p=0.0000000). Children 1 to 2 and 6 to 9 years who were part of the target group of mumps vaccination since 1998, they had higher seroprevalence than the group of 3 to 5 years unvaccinated. Conclusions. Seropositivity in children aged 1 to 2 and 6 to 9 years was probably attributable to vaccination during 1998-2000 and in other age groups to natural exposure related to time elapsed in each birth cohort until the study recruitment.


REFERENCES

  1. Rubin S, Eckhaus M, Rennick LJ, Bamford CCG, Duprex WP. Molecular biology, pathogenesis and pathology of mumps virus. J Pathol. 2015;235(2):242-25. https://doi.org/10.1002/path.4445

  2. Ternavasio-de la Vega HG, Boronat M, Ojeda A, García-Delgado Y, Ángel- Moreno A, Carranza-Rodríguez C, et al. Mumps Orchitis in the Post-Vaccine Era (1967 y 2009). A Single-Center Series of 67 Patients and Review of Clinical Outcome and Trends. Medicine. 2010;89(2):96-116. https://doi. org/10.1097/MD.0b013e3181d63191

  3. Werner Ca. Mumps orchitis and testicular atrophy. I. occurrence. Ann Intern Med. 1950;32(6):1066-9. https://doi.org/10.7326/0003-4819-32-6-1066

  4. Prinz W, Taubert HL. Mumps in pubescent females and its effect on later reproductive function. Gynaecologia 1969;167(1):23-27. https://doi. org/10.1159/000302156

  5. Plotkin SA, Rubin SA. Mumps vaccine. In: Plotkin SA, Orenstein W, Offit P, eds. Vaccines, 5th ed. Philadelphia: WB Saunders, 2008:435-65.

  6. Baum GB, Litman N. Mumps virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 5th ed. Philadelphia: Churchil Livingstone, 2000:1776-981.

  7. ACIP. Prevention of measles, rubella, congenital rubella syndrome and mumps, 2013. Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013;62(4):1-40.

  8. Sosa-Martínez J, Lira MS, Benavides L. Investigación de anticuerpos inhibidores de la hemaglutinación del virus de la parotiditis epidémica en personas de diferentes edades. Bol Med Hosp Infant Mex. 1964;21:330-7.

  9. Golubjatnikov R, Leppla L, Filloy L. Anticuerpos inhibidores de la hemaglutinación para sarampión, rubéola y parotiditis. Investigación de su prevalencia en una comunidad de la meseta de México. Salud Publica Mex. 1970;12(5):603-9.

  10. Gutiérrez G, Ruiz-Gómez J, Bustamante M. Encuesta serológica en niños de la Ciudad de México. V. Investigación de anticuerpos contra la parotiditis. Salud Publica Mex. 1971;13(4):483-7.

  11. Ruiz-Gómez J, Silva-Acosta C. Seroepidemiología del sarampión, rubéola y parotiditis en la República Mexicana. V. Parotiditis. Salud Publica Mex. 1978;20(1):27-31.

  12. Consejo Nacional de Vacunación. Manual de Vacunación 2008-2009. Capítulo 4. Vacunas y toxoides. México: Secretaría de Salud, 2008;68-75.

  13. Fernández de Castro J, Bennett JV, Gallardo-Rincón H, Alvarez y Muñoz MT, Partida-Sánchez LAE, Santos JI. Evaluation of immunogenicity and side effects of triple viral vaccine (MMR) in adults, given by two routes: subcutaneous and respiratory (aerosol). Vaccine. 2005;23(8):1079- 84. https://doi.org/10.1016/j.vaccine.2004.08.018

  14. Díaz-Ortega JL, Bennett JV, Castañeda D, Arellano D, Martinez D, Fernandez de Castro J. Safety and antibody responses to aerosolized MMR II vaccine in adults: an exploratory study. World J Vaccines. 2012;2(2):55-60. https://doi.org/10.4236/wjv.2012.22008

  15. Díaz-Ortega JL, Bennett JV, Castañeda-Desales D, Arellano-Quintanilla DM, Martínez D, Fernandez de Castro J. Booster immune response in children of 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection. Vaccine. 2014;32(29):3680-6. https://doi.org/10.1016/j.vaccine.2014.04.031

  16. Bennett JV, Fernández-de Castro J, Martínez-Poblete R, García-Alcántara ML, Gallardo-Díaz E, Molina-Ángeles MA, et al. A new rapid and promising approach to aerosol immunization: inflatable bags and valved masks. Vaccine. 2009;27(34):4571-5. https://doi.org/10.1016/j.vaccine.2009.05.086

  17. Díaz-Ortega JL, Bennett JV, Castañeda D, Valdespino-Gómez JL, Fernández de Castro J. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: Comparisons with injected MMR. Vaccine. 2010;28(3):692-8. https://doi.org/10.1016/j.vaccine.2009.10.083

  18. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, et al. Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis. 2007;13(1):12-7. https://doi.org/10.3201/eid1301.060649

  19. Kutty PK, McLean HQ, Lawler J, Schulte C, Hudson JM, Blog D, Wallace G. Risk factors for transmission of mumps in a highly vaccinated population in Orange County, NY, 2009-2010. Pediatr Infect Dis J. 2014;33(2):121-5. https://doi.org/10.1097/INF.0000000000000020

  20. Livingston KA, Rosen JB, Zucker JR, Zimmerman CM. Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. Vaccine 2014;32(3):369-74. https://doi. org/10.1016/j.vaccine.2013.11.021

  21. Valdespino JL, Olaiz G, López-Barajas MP, Mendoza L, Palma O, Velásquez O, et al. Vivienda, población y utilización de servicios de salud. En: Encuesta Nacional de Salud 2000. Cuernavaca, Morelos: Instituto Nacional de Salud Pública, 2003:1-292.

  22. Bassols-Batalla A. México: Formación de regiones económicas. Influencias, Factores y sistemas. 2ª ed. Ciudad de México, Instituto de Investigaciones Económicas de la Universidad Nacional Autónoma de México, 1983:43-71.

  23. Sepúlveda J, Tapia-Conyer R, Velásquez O, Valdespino JL, Olaiz-Fernández G, Kuri P, et al. Diseño y metodología de la Encuesta Nacional de Salud 2000. Salud Publica Mex. 2007;49(3):427-32. https://doi.org/10.1590/ S0036-36342007000900015

  24. Institut VirionSerion GmbH. Serion ELISA classic Mumps Virus IgG/ IgM. 2012 [citado 2016, febrero 19]. Disponible en: http://www.virionserion. de/en/products/serion-elisa-classic-kursiu/childrens-disease/mumpsvirus. html

  25. Londoño F. Metodología de la investigación epidemiológica. 5ª ed. Bogotá: Manual Moderno, 2014:112-27.

  26. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLos Med. 2007;4(10):e297. https://doi.org/10.1371/journal.pmed.0040297

  27. Ruiz-Gómez J, Valdespino JL, Olaiz-Fernández G, Arias-Toledo E, Sepúlveda J. Encuesta serológica nacional del sarampión en niños: evidencias para su eliminación. Salud Publica Mex. 2007;49 (supl 3):S370-6. https:// doi.org/10.1590/S0036-36342007000900008

  28. Kutty PK, Kruszon-Moran DM, Dayan GH, Alexander JP, Williams NJ, Garcia PE, et al. Seroprevalence of antibody to mumps virus in the US population, 1999–2004. J Infect Dis. 2010;202(5):667-74. https://doi. org/10.1086/655394

  29. Santacruz-Sanmartín E, Hincapié-Palacio D, Ospina MC, Perez-Toro O, Bernal-Restrepo LM, Buitrago-Giraldo S, et al. Seroprevalence of mumps in an epidemic period in Medellín, Colombia. Vaccine. 2015;33(42):5606- 12. https://doi.org/10.1016/j.vaccine.2015.08.088

  30. Anderson RM, May RM. Infectious diseases of humans. USA: Oxford Science Publications, 1991:12-24.

  31. Fine PEM, Mulholland K. Community immunity. In: Plotkin SA, Orenstein W, Offit P, eds. Vaccines, 5th ed. Philadelphia: WB Saunders, 2008:1573-92.

  32. Mackenzie DG, Hallam N, Stevenson J. Younger teenagers are also at risk of mumps outbreaks. BMJ 2005;330:1509. https://doi.org/10.1136/ bmj.330.7506.1509

  33. Rau CJ, Danovaro-Holliday MC. Letter to the Editor. Re: Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. Vaccine. 2015;33(29):3273. https://doi. org/10.1016/j.vaccine.2014.09.005

  34. Del Valle A, García AA, Barrón BL. Detection of mumps virus genotype H in two previously vaccinated patients from Mexico City. Arch Virol. 2016;161(6)1639-44. https://doi.org/10.1007/s00705-016-2770-6




2020     |     www.medigraphic.com